UBS Maintains NuVasive to Buy with Price Target $71.00

Brokerage firm UBS Maintains its rating on NuVasive(NASDAQ:NUVA). In a research note issued to the investors, the brokerage major Raises the price-target to $71.00 per share. The shares have been rated Buy. The rating by UBS was issued on Jul 28, 2016.

In a different note, On Jul 27, 2016, Barclays said it Maintains its rating on NuVasive. In the research note, the firm Raises the price-target to $63.00 per share. The shares have been rated ‘Overweight’ by the firm. On Jul 27, 2016, Jefferies said it Maintains its rating on NuVasive. In the research note, the firm Raises the price-target to $63.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 13, 2016, JP Morgan said it Upgrades its rating on NuVasive. In the research note, the firm Raises the price-target to $55.00 per share. The shares have been rated ‘Overweight’ by the firm. On May 27, 2016, Barclays said it Upgrades its rating on NuVasive. In the research note, the firm Raises the price-target to $58.00 per share. The shares have been rated ‘Overweight’ by the firm.

NuVasive (NUVA) shares turned negative on Thursdays trading session with the shares closing down -0.05 points or -0.08% at a volume of 4,40,767. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $63.26. The peak price level was also seen at $63.26 while the days lowest was $62.2. Finally the shares closed at $62.71. The 52-week high of the shares is $63.43 while the 52-week low is $36.81. According to the latest information available, the market cap of the company is $3,149 M.

NuVasive(NUVA) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $236.21M. Analysts had an estimated revenue of $232.86M. Earnings per share were $0.40. Analysts had estimated an EPS of $0.36.

Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, Jason Hannon (EVP, International) sold 14,534 shares at $57.92 per share price.Also, On Jan 7, 2016, Patrick Miles (President and COO) sold 10,723 shares at $54.41 per share price.On Dec 7, 2015, Quentin S. Blackford (CFO and CAO) sold 15,000 shares at $51.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Company’s software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *